Trading at a very low 13.77 P/E ratio.
Short interest is quiet high at 9.15%, which could ignite a rally.
Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML.
Company profile
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Short interest is quiet high at 9.15%, which could ignite a rally.
Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML.
Company profile
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.